New cancer drug SHR-7782 enters human testing

NCT ID NCT07123129

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug, SHR-7782, in 200 adults with advanced malignant cancer that has not responded to standard treatments. The main goals are to find the safest dose and check for side effects, while also watching for any tumor shrinkage. Participants must have measurable tumors and be in relatively good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-7782 injection
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 200 participants, so it is too soon to know if SHR-7782 is safe or effective. Many early-stage cancer drugs do not advance to later testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.